Fresenius Medical Care beats quarterly profit estimates, sticks to 2026 outlook

Fresenius Medical Care beats quarterly profit estimates, sticks to 2026 outlook

Aug 3 (Reuters) – Fresenius Medical Care on Monday reported second-quarter operating income well ahead of ​market expectations and reaffirmed its full-year outlook, ‌as its cost-cutting programme and favourable U.S. reimbursement rates offset a deepening decline in patient ​treatment volumes.

The world’s largest dialysis provider ​posted operating income excluding special items ⁠of €569 million for the three months ended ​June 30, above a consensus forecast of €515 ​million. Revenue rose to €4.86 billion, edging past estimates of €4.79 billion, while basic earnings per share of €0.81 ​beat the €0.68 consensus.

Fresenius reaffirmed guidance for revenue ​growth to be “broadly flat” in 2026 and operating income ‌to ⁠grow within “a range between a positive and negative mid-single digit percent growth rate”.

UBS Fined $125 Million by US Regulators for Anti-Money Laundering Violations

The company said operating income growth in the ​first half “was ​in line ⁠with our planned phasing for the full year”.

This points to ​management’s expectation that a temporary Medicare ​payment ⁠boost for certain new drugs and equipment, known as TDAPA, which has flattered profits ⁠so ​far this year, will ​taper off and start working against earnings in the second ​half.

About the Author

VoM News Desk

News Desk VoM

VoM News Desk -is an online web portal in jammu Kashmir offers regional, National & global news.